Navigation Links
VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
Date:11/17/2009

MOUNTAIN VIEW, Calif., Nov. 17 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) plans to announce the results from the avanafil REVIVE (TA-301) phase 3 clinical trial on November 18th prior to market open. The announcement will be followed by a webcast and conference call at 8:30 a.m. Eastern time.

Conference Call Information

Domestic callers: 1-800-776-0853

International callers: 1-913-312-0980

Webcast information: http://ir.vivus.com. A webcast replay will be available on the VIVUS web site for 30 days.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), has recently completed phase 3 clinical trials for the treatment of obesity. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

    CONTACT:

    VIVUS, Inc.                Investor Relations:  The Trout Group
    Timothy E. Morris                               Brian Korb
    Chief Financial Officer                         646-378-2923
    650-934-5200

                                  Media Relations:  Pure Communications, Inc.
                                                    Dan Budwick
                                                    973-271-6085

SOURCE VIVUS, Inc.


'/>"/>
SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
2. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
3. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
4. VIVUS Announces Promotion of Peter Tam to President
5. VIVUS to Present at Lazard Capital Markets Healthcare Conference
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
9. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
10. ViroPharma to Present at Three Upcoming Healthcare Conferences
11. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... 7, 2017 Endo International plc (NASDAQ: ... the Hon. Joseph R. Goodwin , U.S. District ... West Virginia , entered a case management order ... System Products Liability Litigation (the "MDL") that includes a ... provide expert disclosures on specific causation within one hundred ...
(Date:6/5/2017)... Neb. , June 5, 2017 ... in the United States . ... helps a fallen person up to an almost-standing ... easily assembled and operated by one assistant and does ... It is simple enough that a child can operate ...
(Date:5/30/2017)... Corp. (NASDAQ: DRIO), a leading global digital health company with mobile ... presenting at the 7th annual LD Micro Invitational on Tuesday, June ... of DarioHealth will be giving the presentation and meeting with investors. ... 7th, 2017 at the Luxe Sunset Bel Air Hotel and will ... About LD Micro LD Micro was founded ...
Breaking Medicine Technology:
(Date:6/27/2017)... ... June 27, 2017 , ... ... Association’s SUNucate efforts, Louisiana became the sixth state to pass legislation which ... Governor John Bel Edwards’ signature, Louisiana joins the states of Alabama, Arizona, Florida, ...
(Date:6/27/2017)... ... June 27, 2017 , ... A January 18th article ... a staggering $6.81 billion by the year 2024 according to a new report. The ... than those made from titanium. Los Angeles area clinic Beverly Hills Periodontics & Dental ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... personal financial planning services to residents of southern New Hampshire, is teaming up ... promises to fight hunger and homelessness in the region. , New Horizons for ...
(Date:6/27/2017)... ... June 27, 2017 , ... Atmosera , a premier ... Azure Services . The trusted, transparent, and secure solution for the cloud enablement ... base. Atmosera’s next generation services include integrated capabilities for public, private, and hybrid ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... Dr. Richard ... recent renovation of his practice, Advanced Periodontics and Dental Implant Center of Connecticut. As ... the administrative and waiting areas. The renovations are intended to improve patient comfort while ...
Breaking Medicine News(10 mins):